



CERTIFICATE OF MAILING PURSUANT TO 37 C.F.R. SECTION 1.8

I hereby certify that this correspondence is being deposited, pursuant to 37 C.F.R. Section 1.8, with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on this 15th of May, 2002.

By

Richard R. Muccino

Richard R. Muccino

Reg. No. 32,538

date

15 May 02

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Patent Application:
Brandt et al.

Group Art Unit:

Serial No: 10/081,309, filed February 21, 2002

Examiner:

For: PEG CONJUGATES OF NK4

Supplementary Response Pursuant To 37 C.F.R. Section 1.115

Nutley, New Jersey 07110
May 15 2002

Commissioner for Patents
Washington, D.C. 20231

This Supplementary Response pursuant to 37 C.F.R. Section 1.115 is in response to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Sequence Disclosures dated 22 March 2002 in the above-identified patent application.

Applicant requests that the Examiner consider the following response and pass the above-identified application to issue.

RESPONSE

As set out above, applicant has submitted this Supplementary Response in reply to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Sequence Disclosures in the above-identified patent application.

In response to this Notice, applicant has submitted herewith a Sequence Listing of the nucleotide and/or amino acid sequences in the above-identified patent application on paper copy in accord with 37 C.F.R. Section 1.821(c) and in computer readable form in accord with 37 C.F.R. Section 1.821(e). Applicant has also filed herewith a statement pursuant to 37 C.F.R. Section 1.821(f) that the content of the paper copy and computer readable copy are the same and a statement pursuant to 37 C.F.R. Section 1.821(g) that the submission of the paper copy and the computer readable copy includes no new matter.

In accord with 37 C.F.R. Sections 1.821(c) and 1.821(d), applicant has provided this response to include references to each sequence disclosed in the Sequence Listing by use of the separate identifiers written as SEQ ID NO:1, SEQ ID NO:2, etc. Applicant has already provided references in the application as filed to each sequence disclosed in the Sequence Listing by use of the separate identifiers, written as SEQ ID NO:1, SEQ ID NO:2, etc..

In view of the foregoing response, applicant requests allowance of the claims pending in this application. Applicant requests the Examiner to

telephone the undersigned attorney should the Examiner have any questions or comments which might be most expeditiously handled by a telephone conference.

Applicant's attorney authorizes the Examiner to charge Deposit Account 12-2525 if there are any additional charges in connection with this response and amendment.

Respectfully submitted,
Brandt et al.

By Richard R. Muccino
Richard R. Muccino
Reg. No. 32,538
Attorney for Applicant(s)

Direct communications to:
George W. Johnston, Esq.
Hoffmann-La Roche Inc.
340 Kingsland Street
Nutley, New Jersey 07110-1199
Telephone: (973) 235-3656
Telefax: (973) 235-2363